BiotechTube

"The MaP Study": Mapping the Patient Journey in MMA and PA

PreclinicalCompleted
0 views this week 0 watching
0
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Methylmalonic Acidemia, Propionic Acidemia

Conditions

Methylmalonic Acidemia, Propionic Acidemia

Trial Timeline

Mar 20, 2018 → May 29, 2021

NCT ID
NCT03484767

About "The MaP Study": Mapping the Patient Journey in MMA and PA

"The MaP Study": Mapping the Patient Journey in MMA and PA is a preclinical stage product being developed by Moderna for Methylmalonic Acidemia, Propionic Acidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03484767. Target conditions include Methylmalonic Acidemia, Propionic Acidemia.

Clinical Trials (1)

NCT IDPhaseStatus
NCT03484767PreclinicalCompleted

Competing Products

4 competing products in Methylmalonic Acidemia, Propionic Acidemia

See all competitors
ProductCompanyStageHype Score
mRNA-3705ModernaPhase 2
0
mRNA-3704ModernaPhase 2
0
mRNA-3705ModernaPhase 2
0
Carglumic AcidRecordatiPre-clinical
30